OVID (Ovid Therapeutics) E10: $-1.20 (As of Mar. 2026)


OVID Ovid Therapeutics Inc OVID
48 GF Score
Price $2.69
GF Value $8.46
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Ovid Therapeutics E10?

Ovid Therapeutics OVID -1.28% 48 E10 is $-1.20 as of Mar. 2026. GuruFocus rates OVID with a GF Score™ of 48/100 and a GF Value™ of $8.46 (Possible Value Trap). The stock has 6 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Ovid Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was $-0.120. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-1.20 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-01), Ovid Therapeutics's current stock price is $2.69. Ovid Therapeutics's E10 for the quarter that ended in Mar. 2026 was $-1.20. Ovid Therapeutics's Shiller PE Ratio of today is .


Ovid Therapeutics  (NAS:OVID) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Ovid Therapeutics E10 Related Terms


Ovid Therapeutics E10 Historical Data

* Premium members only.

The historical data trend for Ovid Therapeutics's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Ovid Therapeutics E10 Chart

Ovid Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -1.19

Ovid Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 -1.23 -1.19 -1.20

OVID vs ARTV, CCCC, RZLT: E10 Comparison

For the Biotechnology subindustry, Ovid Therapeutics's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ovid Therapeutics Shiller PE Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Ovid Therapeutics's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Ovid Therapeutics's Shiller PE Ratio falls into.


OVID
48GF Score
Ovid Therapeutics Inc OVID
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Ovid Therapeutics E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Ovid Therapeutics's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=-0.12/330.2130*330.2130
=-0.120

Current CPI (Mar. 2026) = 330.2130.

Ovid Therapeutics Quarterly Data

per share eps CPI Adj_EPS
201606 -0.275 241.018 -0.377
201609 -0.295 241.428 -0.403
201612 -0.386 241.432 -0.528
201703 -1.392 243.801 -1.885
201706 -0.570 244.955 -0.768
201709 -0.380 246.819 -0.508
201712 -0.450 246.524 -0.603
201803 -0.540 249.554 -0.715
201806 -0.530 251.989 -0.695
201809 -0.530 252.439 -0.693
201812 -0.520 251.233 -0.683
201903 -0.460 254.202 -0.598
201906 -0.340 256.143 -0.438
201909 -0.430 256.759 -0.553
201912 -0.350 256.974 -0.450
202003 -0.370 258.115 -0.473
202006 -0.410 257.797 -0.525
202009 -0.280 260.280 -0.355
202012 -0.340 260.474 -0.431
202103 2.530 264.877 3.154
202106 -0.230 271.696 -0.280
202109 -0.170 274.310 -0.205
202112 -0.380 278.802 -0.450
202203 -0.230 287.504 -0.264
202206 -0.210 296.311 -0.234
202209 -0.170 296.808 -0.189
202212 -0.160 296.797 -0.178
202303 -0.190 301.836 -0.208
202306 -0.180 305.109 -0.195
202309 -0.160 307.789 -0.172
202312 -0.210 306.746 -0.226
202403 -0.170 312.332 -0.180
202406 0.120 314.175 0.126
202409 -0.200 315.301 -0.209
202412 -0.130 315.605 -0.136
202503 -0.140 319.799 -0.145
202506 -0.060 322.561 -0.061
202509 -0.170 324.800 -0.173
202512 0.060 324.054 0.061
202603 -0.120 330.213 -0.120

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of $-1.20 mean?
Ovid Therapeutics (OVID) has a E10 of $-1.20 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ovid Therapeutics and its competitors.
Is Ovid Therapeutics' E10 too high?
Ovid Therapeutics' current E10 is $-1.20. Overall, Ovid Therapeutics has a GF Score™ of 48/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Ovid Therapeutics' E10 compare to ARTV and CCCC?
Ovid Therapeutics' E10 of $-1.20 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Biotechnology company?
A good E10 depends on the Biotechnology industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Ovid Therapeutics and its competitors. Ovid Therapeutics's current E10 is $-1.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ovid Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Ovid Therapeutics (OVID) is currently considered Possible Value Trap. The stock's GF Value™ is $8.46, compared to a current price of $2.69 — trading 68.2% below its estimated fair value. The current E10 is $-1.20. Ovid Therapeutics' overall GF Score™ is 48/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Ovid Therapeutics (OVID), the current E10 is $-1.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Ovid Therapeutics (OVID) Overvalued in 2026?

Based on GuruFocus' analysis, Ovid Therapeutics stock appears to be undervalued. The current stock price of $2.69 is trading 68.2% below its estimated GF Value™ of $8.46. GuruFocus considers Ovid Therapeutics to be Possible Value Trap.

Key valuation signals for OVID:

  • E10: $-1.20
  • GF Value™: $8.46 vs. price of $2.69 (68.2% below fair value)
  • GF Score™: 48/100 with 6 warning signs

No single metric tells the full story. See the OVID stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Ovid Therapeutics Business Description

Other Exchanges 1OT:Germany
Address 441 Ninth Avenue, 14th Floor, New York, NY, USA, 10001
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.
48GF Score

Get the complete analysis for OVID

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.69
Price
$8.46
GF Value